These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 16832827)

  • 1. Epidemiology in the pharmaceutical Industry: A Canadian perspective.
    Rawson NS; De Souza LR
    Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):758-62. PubMed ID: 16832827
    [No Abstract]   [Full Text] [Related]  

  • 2. Commentary: Canadian Association for Population Therapeutics: the past, present and future - a personal viewpoint and a call to action.
    Rawson NS
    J Popul Ther Clin Pharmacol; 2011; 18(2):e403-6. PubMed ID: 22577132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proper preference-based outcome measures in economic evaluations of pharmaceutical interventions.
    Gafni A
    Med Care; 1996 Dec; 34(12 Suppl):DS48-58. PubMed ID: 8969314
    [No Abstract]   [Full Text] [Related]  

  • 4. Commentary: Epidemiology and the pharmaceutical industry: an inside perspective.
    Haas J
    Int J Epidemiol; 2008 Feb; 37(1):53-5; discussion 65-8. PubMed ID: 18184672
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacoepidemiology: the industry's perspective.
    Tilson HH
    J Rheumatol Suppl; 1988 Oct; 17():28-33. PubMed ID: 3204617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A survey of individuals in US-based pharmaceutical industry HEOR departments: attitudes on policy topics.
    Neumann PJ; Saret CJ
    Expert Rev Pharmacoecon Outcomes Res; 2013 Oct; 13(5):657-61. PubMed ID: 24138650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commentary: pharmacoeconomics and outcomes research: expanding the healthcare "outcomes" market.
    Hay JW; Yu WM
    Value Health; 2000; 3(3):181-5. PubMed ID: 16464182
    [No Abstract]   [Full Text] [Related]  

  • 8. A cardiovascular atlas for Canada.
    Smith ER
    Can J Cardiol; 2003 Jun; 19(7):854-5. PubMed ID: 12813619
    [No Abstract]   [Full Text] [Related]  

  • 9. [Blurred vision due to transparency?].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2012 Nov; 35(11):393. PubMed ID: 23213708
    [No Abstract]   [Full Text] [Related]  

  • 10. The quiet revolution: outsourcing in pharma.
    Crossley R
    Drug Discov Today; 2004 Aug; 9(16):694. PubMed ID: 15341780
    [No Abstract]   [Full Text] [Related]  

  • 11. Legalized importation of Canadian prescription drugs: short-term solution to a long-term problem.
    Teufel AT
    J Contemp Health Law Policy; 2006; 22(2):383-408. PubMed ID: 17117702
    [No Abstract]   [Full Text] [Related]  

  • 12. Some statistical issues in project prioritization in the pharmaceutical industry.
    Senn S
    Stat Med; 1996 Dec; 15(24):2689-702. PubMed ID: 8981680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deal watch: Ablynx and Merck Serono collaborate on next-generation antibody products.
    Nat Rev Drug Discov; 2008 Nov; 7(11):881. PubMed ID: 18974745
    [No Abstract]   [Full Text] [Related]  

  • 14. The US drug safety system: role of the pharmaceutical industry.
    Gibson BR; Suh R; Tilson H
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):110-4. PubMed ID: 17724741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health outcomes in low-income children with current asthma in Canada.
    To T; Dell S; Tassoudji M; Wang C
    Chronic Dis Can; 2009; 29(2):49-55. PubMed ID: 19281690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On salvaging the pharmaceutical sciences in Canada?
    Jamali F; Pasutto FM
    J Pharm Pharm Sci; 1999; 2(2):36-7. PubMed ID: 10952766
    [No Abstract]   [Full Text] [Related]  

  • 17. Considerations and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis.
    Bansback N; Maetzel A; Drummond M; Anis A; Marra C; Conway P; Boers M; Tugwell P; Boonen A
    J Rheumatol; 2007 May; 34(5):1178-83. PubMed ID: 17477483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial overview: whither the pharmaceutical industry?
    Gund P; Maliski E; Brown F
    Curr Opin Drug Discov Devel; 2005 May; 8(3):296-7. PubMed ID: 15892242
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug safety: a contrarian's point of view.
    Cobert B
    Food Drug Law J; 2007; 62(3):501-12. PubMed ID: 17915392
    [No Abstract]   [Full Text] [Related]  

  • 20. Hypertension control: improved, but not enough!
    Alderman MH
    Am J Hypertens; 2007 Apr; 20(4):347. PubMed ID: 17386338
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.